{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/pyelonephritis-acute/prescribing-information/cefalexin/","result":{"pageContext":{"chapter":{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin","depth":2,"htmlHeader":"<!-- begin field 30ed69c9-03b6-4bd2-8df3-e5351b371ce2 --><h2>Cefalexin</h2><!-- end field 30ed69c9-03b6-4bd2-8df3-e5351b371ce2 -->","summary":"","htmlStringContent":"<!-- begin item 25503612-c86a-47cf-b6cc-d73e9e5e0efc --><!-- end item 25503612-c86a-47cf-b6cc-d73e9e5e0efc -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","lastRevised":"Last revised in November 2020","chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","fullItemName":"Management","slug":"management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"f7593450-461d-5c60-b2fb-c3eb314bd875","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 8e76024f-c443-4db4-bed1-a99a00e4bf0c --><h3>Contraindications and cautions</h3><!-- end field 8e76024f-c443-4db4-bed1-a99a00e4bf0c -->","summary":"","htmlStringContent":"<!-- begin item 4ccf3576-f131-4ed9-b209-a99a00e4be6c --><!-- begin field 80accdc0-0b57-4743-b6bb-a99a00e4bf0c --><ul><li><strong>Do not prescribe cefalexin in people with: </strong><ul><li>A known allergy to the cephalosporin group of antibiotics or a history of immediate hypersensitivity to penicillin and other beta-lactams.</li></ul></li><li><strong>Prescribe cefalexin with caution in people with:</strong><ul><li>Sensitivity to penicillin and other beta lactams. About 0.5–6.5% of penicillin-sensitive people will also be allergic to cephalosporins.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 80accdc0-0b57-4743-b6bb-a99a00e4bf0c --><!-- end item 4ccf3576-f131-4ed9-b209-a99a00e4be6c -->","subChapters":[]},{"id":"3ca5b3cc-18be-5e89-a49e-4ce298d2586a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 5326f908-5787-44a3-8e25-a99a00e4d0a4 --><h3>Adverse effects</h3><!-- end field 5326f908-5787-44a3-8e25-a99a00e4d0a4 -->","summary":"","htmlStringContent":"<!-- begin item 3dd40380-07ad-4b2e-8c8a-a99a00e4d054 --><!-- begin field a995f81e-eb29-487f-a863-a99a00e4d0a4 --><ul><li><strong>Gastrointestinal </strong>— diarrhoea (most common), nausea, vomiting, abdominal discomfort.</li><li><strong>Nervous system</strong> — headache, dizziness.</li><li><strong>Psychiatric </strong>— hallucinations, confusion, agitation.</li><li><strong>Skin</strong> — rash urticaria, angioedema.<ul><li><strong>Rarely:</strong> erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis (exanthematic necrolysis)</li></ul></li><li><strong>Other adverse effects include:</strong> <ul><li>Anaphylaxis.</li><li>Arthralgia and myalgia.</li><li>Eosinophilia, neutropenia, thrombocytopenia, haemolytic anaemia. </li><li>Genital and anal pruritus.</li><li>Hepatitis, cholestatic jaundice.</li><li>Interstitial nephritis (rarely).</li><li>Pseudomembranous colitis (for more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field a995f81e-eb29-487f-a863-a99a00e4d0a4 --><!-- end item 3dd40380-07ad-4b2e-8c8a-a99a00e4d054 -->","subChapters":[]},{"id":"f14f7c4c-79b3-5c0e-b8f4-d72ae5aa693d","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field ae08cd00-4747-49f7-a3e2-a99a00e4e067 --><h3>Drug interactions</h3><!-- end field ae08cd00-4747-49f7-a3e2-a99a00e4e067 -->","summary":"","htmlStringContent":"<!-- begin item d1dac5ea-b90f-41f0-b4a3-a99a00e4e02a --><!-- begin field 095ed169-725f-4bae-8077-a99a00e4e067 --><ul><li><strong>Aminoglycosides </strong>(for example, gentamicin) — possible increased risk of nephrotoxicity. Routine renal monitoring for the aminoglycoside is usually adequate.</li><li><strong>Oral anticoagulants </strong>(warfarin and phenindione) — cefalexin may enhance the anticoagulant effect. Monitor the international normalized ratio (INR) closely during concomitant use. </li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of cefalexin.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li><li><strong>Probenecid</strong> — renal excretion of cefalexin is inhibited. However, no dose adjustment is normally required.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field 095ed169-725f-4bae-8077-a99a00e4e067 --><!-- end item d1dac5ea-b90f-41f0-b4a3-a99a00e4e02a -->","subChapters":[]},{"id":"05ec06f3-9a2b-5c57-b493-de07d51c9962","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 8ce7cf58-d99f-4935-b0aa-a99a00e50218 --><h3>Pregnancy and breastfeeding</h3><!-- end field 8ce7cf58-d99f-4935-b0aa-a99a00e50218 -->","summary":"","htmlStringContent":"<!-- begin item be1793c9-3bd2-4199-9ac3-a99a00e5006d --><!-- begin field ea5ae0d0-6919-493b-9202-a99a00e50218 --><h4>Pregnancy</h4><ul><li>Cefalexin is not known to be harmful in pregnancy.</li></ul><h4>Breastfeeding</h4><ul><li>Trace amounts of cefalexin are found in breastmilk — it is not known to be harmful to breastfed children.<ul><li>Cephalosporins (and penicillins) are the antibiotics of choice in women who are breastfeeding.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">Kearney, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/pyelonephritis-acute/references/\">BNF 76, 2018</a>]</p><!-- end field ea5ae0d0-6919-493b-9202-a99a00e50218 --><!-- end item be1793c9-3bd2-4199-9ac3-a99a00e5006d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}